Scilex Holding Company
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.37
- Today's High:
- $2.54
- Open Price:
- $2.47
- 52W Low:
- $2.37
- 52W High:
- $16.9
- Prev. Close:
- $2.41
- Volume:
- 707262
Company Statistics
- Market Cap.:
- $462.07 million
- Book Value:
- 0.07
- Revenue TTM:
- $46.46 million
- Operating Margin TTM:
- -169.27%
- Gross Profit TTM:
- $27.24 million
- Profit Margin:
- -115.77%
- Return on Assets TTM:
- -45.42%
- Return on Equity TTM:
- 0%
Company Profile
Scilex Holding Company had its IPO on 2021-03-05 under the ticker symbol SCLX.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Scilex Holding Company has a staff strength of 100 employees.
Stock update
Shares of Scilex Holding Company opened at $2.47 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.37 - $2.54, and closed at $2.44.
This is a +1.24% increase from the previous day's closing price.
A total volume of 707,262 shares were traded at the close of the day’s session.
In the last one week, shares of Scilex Holding Company have slipped by -21.29%.
Scilex Holding Company's Key Ratios
Scilex Holding Company has a market cap of $462.07 million, indicating a price to book ratio of 0 and a price to sales ratio of 14.1851.
In the last 12-months Scilex Holding Company’s revenue was $46.46 million with a gross profit of $27.24 million and an EBITDA of $-74500000. The EBITDA ratio measures Scilex Holding Company's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Scilex Holding Company’s operating margin was -169.27% while its return on assets stood at -45.42% with a return of equity of 0%.
In Q2, Scilex Holding Company’s quarterly earnings growth was a positive 0% while revenue growth was a positive 58.7%.
Scilex Holding Company’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Scilex Holding Company’s profitability.
Scilex Holding Company stock is trading at a EV to sales ratio of 21.1847 and a EV to EBITDA ratio of -14.7839. Its price to sales ratio in the trailing 12-months stood at 14.1851.
Scilex Holding Company stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $126.46 million
- Total Liabilities
- $103.58 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $146000
- Dividend Payout Ratio
- 0%
Scilex Holding Company ended 2024 with $126.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $126.46 million while shareholder equity stood at $10.42 million.
Scilex Holding Company ended 2024 with $0 in deferred long-term liabilities, $103.58 million in other current liabilities, 15000.00 in common stock, $-433316000.00 in retained earnings and $13.48 million in goodwill. Its cash balance stood at $34.12 million and cash and short-term investments were $34.12 million. The company’s total short-term debt was $35,132,000 while long-term debt stood at $0.
Scilex Holding Company’s total current assets stands at $69.25 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.57 million compared to accounts payable of $11.41 million and inventory worth $3.11 million.
In 2024, Scilex Holding Company's operating cash flow was $0 while its capital expenditure stood at $146000.
Comparatively, Scilex Holding Company paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.44
- 52-Week High
- $16.9
- 52-Week Low
- $2.37
- Analyst Target Price
- $
Scilex Holding Company stock is currently trading at $2.44 per share. It touched a 52-week high of $16.9 and a 52-week low of $16.9. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $4.47 and 200-day moving average was $6.51 The short ratio stood at 5.18 indicating a short percent outstanding of 0%.
Around 4280.4% of the company’s stock are held by insiders while 1056.5% are held by institutions.
Frequently Asked Questions About Scilex Holding Company
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.